• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, April 1, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Could a diabetes drug be used for Motor Neurone Disease?

Bioengineer by Bioengineer
February 11, 2018
in Biology
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Lancaster University

Could a diabetes drug be used for Motor Neurone Disease?

A diabetes drug could one day be used to treat neurodegenerative diseases like Motor Neurone Disease (MND), Alzheimer's and Parkinson's.

Researchers at Lancaster University in the UK are to conduct a clinical trial of the diabetes drug Liraglutide, giving it to patients with MND to see whether they improve or not.

MND is a progressive degenerative disorder of motor neurones that leads to muscle weakness and death.

Because neurodegenerative diseases are a "family" of diseases, if a new treatment can be found for one, it may be useful for others too.

The study is led by Professor Hedley Emsley, Consultant Neurologist, with Professor Christian Hölscher from Lancaster University, who previously discovered that Liraglutide can help patients with Alzheimer's.

Professor Holscher said: "This new trial is testing a very promising drug in people with MND, a dreadful condition for which there is no cure. We hope that this drug will make a difference."

There is increasing interest in the idea that drugs licensed for one disease may have some use in a different area.

Professor Emsley said: "Repurposing drugs in this way might lead to treatments for devastating disorders such as MND . Effective treatments for MND are sadly lacking."

There is also the advantage in that an existing drug overcomes the time and cost of drug development which may take up to a decade.

In treating diabetes, Liraglutide and related drugs control the release of insulin by binding to specific protein binding sites in the pancreas.

These cells are also found in cells in the brain where they appear to play a role in maintaining the metabolic health of neurones.

Research showing that activation of these receptor sites with drugs can protect neurones from damage.

###

Media Contact

[email protected]
[email protected]
44-015-245-92612

http://www.lancs.ac.uk

Share14Tweet8Share2ShareShareShare2

Related Posts

Chikungunya Virus Lingers in Joint Macrophages, Causes Chronic Disease

Chikungunya Virus Lingers in Joint Macrophages, Causes Chronic Disease

April 1, 2026
Unveiling How Two Genes Collaborate to Shape Dental and Facial Features

Unveiling How Two Genes Collaborate to Shape Dental and Facial Features

April 1, 2026

Do Your Genes Influence How Lifestyle Choices Affect Aging?

April 1, 2026

Combining Single-Cell Multiomics Unlocks Precise Identification of Rare Cell Types and States

March 31, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1006 shares
    Share 398 Tweet 249
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dorsoventral Hippocampus Reactivates After Aversive Sleep

ALDH1L2 Controls ROS and Pancreatic Cell Changes

Tim-3 Agonist Limits ILC2, Eases Airway Reactivity

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.